We aim to perform a systematic review and meta-analysis to investigate outcomes of treatment strategies for asymptomatic carotid disease. We searched electronic bibliographic sources (MEDLINE, EMBASE, CINAHL and CENTRAL) to identify randomised controlled trials (RCT) reporting comparative outcomes of carotid endarterectomy (CEA), carotid stenting (CAS) and best medical therapy (BMT) in asymptomatic carotid disease. We performed pairwise meta-analysis applying random or fixed-effects models and reported the results as the odds ratio (OR) or risk difference (RD) and 95% confidence interval (CI). We also performed a network meta-analysis and obtained a hierarchy of the competing interventions using rankograms and the surface under the cumulative ranking curve and mean ranks. Stroke and death within 30 days and during follow up were the primary outcome endpoints. Eleven RCTs were identified reporting a total of 8,954 patients. Compared to BMT, CEA reduces the odds of long-term mortality (OR 0.70, 95% CI 0.43, 1.12) and ipsilateral stroke (OR 0.59 95% CI 0.50, 0.71). Network meta-analyses league table demonstrated that BMT is superior to CEA and CAS in terms of perioperative stroke risk and mortality. CEA is the preferred method to reduce the long-term risk of ipsilateral stroke and mortality for patients with asymptomatic carotid disease.
CEA vs. BMT. We identified five RCTs 9, 10, 15, 19, 20 reporting comparative outcomes of CEA vs. BMT for asymptomatic carotid disease, which were published between 1992 and 2015. The overall study population comprised of 5349 patients, 2663 in the CEA group and 2686 in the BMT group. Single antiplatelet therapy in the form of aspirin was used in both treatment groups in all but one trial 20 , in which CEA patients received no antiplatelet therapy. BMT as per current guidelines were used in only one trial 15 , the remaining trail did not provide elements of their BMT protocol. In ACST 1 10 the use of lipid lowering drugs improved significantly during the study period (initially only 7% and at the end of the trail 82%). Follow up ranged between two and ten years. There were no significant differences in baseline demographics and clinical characteristics between the CEA and BMT groups.
CEA vs. CAS. We identified five RCTs 13, 14, [16] [17] [18] reporting comparative outcomes of CEA vs. CAS for asymptomatic carotid disease, which were published between 2008 and 2016. The studies included a total of 3092 patients; 1181 of them underwent CEA and the remaining 1911 underwent CAS. Patients in the CEA group received single antiplatelet therapy with aspirin, whereas those undergoing CAS received dual antiplatelet therapy (aspirin and . Follow up ranged from three to ten years. There were no significant differences in baseline demographics and clinical characteristics between the CEA and BMT groups.
Risk of bias assessment. Random sequence generation and allocation concealment methods were adequately described in all but one trial 14 , which did not state patient selection methods. Due to the nature of intervention, blinding of participants and personnel was not possible resulting in a high risk of performance bias. In six RCTs 9, 10, 12, [18] [19] [20] , blinding of outcome assessors was adequately described, whereas in the remaining trials, this parameter was inadequately reported. Five RCTs 12, 13, 15, 18, 20 were found to have incomplete outcome data (attrition bias). Four RCTs 12, 13, 15, 18 were terminated early, three due to slow enrolment and one due to an unacceptable complication rate in the CEA group 20 . No reporting bias was identified in any of the trials. The risk of bias assessment of the RCTs is summarised in Fig. 2 . The primary end point of the trial was the cumulative incidence of TIA, any stroke and death. CEA vs. BMT. Thirty-day ipsilateral stroke. Data on 30-day ipsilateral stroke were reported in all five studies 9, 10, 15, 19, 20 . In the CEA group (2835 patients), the incidence of 30-day ipsilateral stroke was 1.6%, whereas in the BMT group (2775 patients), the incidence was 0.4% (RD: 0.01, 95% CI: 0.01-0.02, P < 0.00001). We found no evidence of heterogeneity among the studies (I 2 = 0%, P = 0.44). Excluding trials that were judged to be at high risk of bias in two or more domains (ACAS 9 , ACST-1 10 , SPACE-2 12 ) showed no difference between the treatment groups (RD: 0.02, 95% CI: −0.00-0.04, P = 0.11). The recruitment period started after 2000 in one trial only (SPACE-2 trial 12 ), which found no significant difference in 30-day stroke risk between treatments (OR: 5.12, 95% CI: 0.27-95.97, P = 0.27). The GRADE level of evidence for this outcome was judged to be high. Thirty-day mortality. Data on 30-day mortality were reported in all five studies 9, 10, 15, 19, 20 . The 30-day mortality rate was 0.8% in the CEA group (2853 patients) and 0.1% in the BMT group (2775 patients) (RD: 0.01, 95% CI: 0.00-0.01, P = 0.0006). The likelihood of between-study heterogeneity was low (I 2 = 18%, P = 0.3). Excluding trials that were judged to be at high risk of bias in two or more domains (ACAS 9 , ACST-1 10 , SPACE-2 12 ) showed no difference between the treatment groups (RD: 0.01, 95% CI: −0.01-0.03, P = 0.19). The recruitment period started after 2000 in one trial only (SPACE-2 trial 12 ), which reported no mortality within 30 days in either group. The GRADE level of evidence for this outcome was judged to be high.
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Thirty-day ipsilateral minor stroke/TIA. Data on 30-day minor stroke/TIA were reported in three trials 10, 19, 20 . In the CEA group (1807 patients), the incidence of minor stroke/TIA at 30-days was 1.2%, while in the BMT group (1828 patients), the incidence was 0.7% (OR: 1.63, 95% CI: 0.81-3.27, P = 0.17). There was no evidence of significant statistical heterogeneity among the studies (I 2 = 46%, P = 0.16). Excluding the trial that was judged to be at high risk of bias in two or more domains (ACST-1 10 ) showed no difference between the treatment groups (OR: 0.61, 95% CI: 0.14-2.55, P = 0.5). The recruitment period started before 2000 in all trials included in the analysis. The GRADE level of evidence for this outcome was judged to be high.
Thirty-day MI. Data on 30-day MI were reported in three studies 10, 19, 20 . In the CEA group (1807 patients), MI within 30 days of treatment occurred in 1.2% of patients, whereas in the BMT group (1828 patients), MI within 30 days occurred in 0.1% (OR: 12.07, 95% CI: 2.82-51.6, P = 0.0008). There was no evidence of statistical heterogeneity among the studies (I 2 = 0%, P = 0.92). Excluding the trial that was judged to be at high risk of bias in two or more domains (ACST-1 10 ) showed a difference in favour of BMT (OR: 8.78, 95% CI: 1.08-71.21, P = 0.04). The recruitment period started before 2000 in all trials included in the analysis. The GRADE level of evidence for this outcome was judged to be high.
Ipsilateral stroke during follow up. Data on ipsilateral stroke during follow up were reported in four studies 9, 10, 15, 19 . In the CEA group (2627 patients), the incidence of stroke was 8.4%, whereas in the BMT group (2651 patients), ipsilateral stroke occurred in 13.4% of patients (OR: 0.59, 95% CI: 0.49-0.7, P < 0.00001). We found no evidence of statistical heterogeneity among the selected studies (I 2 = 0%, P = 0.49). Excluding trials that were judged to be at high risk of bias in two or more domains (ACAS 9 , ACST-1 10 , AMTEC 15 ) showed no difference between the treatment groups (OR: 0.48, 95% CI: 0.22-1.03, P = 0.06). Only one trial (ACST-1 10 ) provided follow-up data >5 years; it found a significance difference in stroke risk in favour of CEA (OR: 0.59, 95% CI: 0.48-0.73, P < 0.00001). The recruitment period started after 2000 in one trial only (AMTEC 15 ), which found no significant difference in the follow-up stroke risk between treatments (OR: 0.13, 95% CI: 0.01-1.17, P = 0.07). The GRADE level of evidence for this outcome was judged to be high.
Mortality during follow up. Data on long-term mortality were reported in three studies 9, 10, 15 . The mortality rate during follow up was 5.1% in the CEA group (2416 patients) and 6.6% in the BMT group (2418 patients) (OR: 0.75, 95% CI: 0.59-0.96, P = 0.02). We found no evidence of significant statistical heterogeneity among the studies (I 2 = 64%, P = 0.06). All three trials included in this analysis were at high risk of bias in two or more domains. Only one trial (ACST-1 10 ) provided follow-up data >5 years; it found a significance difference in mortality in favour of CEA (OR: 0.56, 95% CI: 0.38-0.84, P = 0.005). The recruitment period started after 2000 in one trial only (AMTEC 15 ), which found no significant difference in mortality risk during follow up between treatments (OR: 0.17, 95% CI: 0.02-1.6, P = 0.12). The GRADE level of evidence for this outcome was judged to be high.
Ipsilateral minor stroke/TIA during follow up. Data on long-term ipsilateral minor stroke/TIA were reported in two trials 19, 20 . During follow up, ipsilateral minor stroke/TIA occurred in 3.2% in the CEA group (247 patients) and in 1.9% in the BMT group (268 patients) (OR: 0.27, 95% CI, 0.12-0.59, P = 0.001). We identified no evidence of statistical heterogeneity (I 2 = 0%, P = 0.86). Both trials were found to be of risk of bias in less than two domains. Neither reported follow up >5 years. The recruitment period started before 2000 in both trials included in the analysis. The GRADE level of evidence for this outcome was judged to be high.
MI during follow up. Data on MI during follow up were reported in two studies 15, 20 . MI during the follow-up period occurred in one patient (1.5%) in the CEA group (67 patients) and in two patients (3.3%) in the BMT group (59 patients) (OR: 0.57, 95% CI: 0.1-3.38, P = 0.54). There was no evidence of statistical heterogeneity between the two studies (I 2 = 44%, P = 0.18). One trial (AMTEC 15 ) was judged to be of high risk of bias in more than two domains; excluding this trial revealed no difference in the risk of MI during follow up between treatment groups (OR: 3, 95% CI: 0.12-76.16, P = 0.51). None of the trials reported follow up >5 years. The recruitment period started after 2000 in one trial only (AMTEC 15 ), which found no significant difference in mortality risk during follow up (OR: 0.14, 95% CI: 0.01-3.12, P = 0.22). The GRADE level of evidence for this outcome was judged to be high.
CEA vs. CAS. Thirty-day ipsilateral stroke. Data on ipsilateral stroke within 30 days of treatment were reported in all five studies 13 1.2% in the CAS group (1991 patients) (RD: −0.01, 95% CI: −0.01-0.00, P = 0.16). There was no evidence of statistical heterogeneity among the studies (I 2 = 0%, P = 0.56). All trials were judged to be at high risk of bias in two or more domains. The recruitment period started before 2000 in one trial (Kentucky); 17 excluding this trial from the analysis showed no difference in the stroke risk within 30 days between CEA and CAS (RD: −0.01, 95% CI: −0.01-0.00, P = 0.15). The GRADE level of evidence for this outcome was judged to be moderate. Thirty-day mortality. Data on 30-day mortality were reported in all five trials 13, 14, [16] [17] [18] . Mortality was 0.7% in the CEA group (1264 patients) and 0.8% in the CAS group (1991 patients) (RD: −0.00, 95% CI: −0.01-0.00, P = 0.27). We found no evidence of statistical heterogeneity (I 2 = 31%, P = 0.21). All trials were judged to be at high risk of bias in two or more domains. Excluding the trial where the recruitment period started before 2000 (Kentucky) 17 revealed no difference in the 30-day mortality risk between CEA and CAS (RD: −0.00, 95% CI: −0.01-0.00, P = 0.26). The GRADE level of evidence for this outcome was judged to be moderate.
Thirty-day ipsilateral minor stroke/TIA. Data on ipsilateral minor stroke/TIA occurring within 30 days of treatment were reported in three trials 13, 14, 17 . In the CEA group (474 patients), the 30-day incidence of minor stroke/ TIA was 1.1%, while in the CAS group (1200 patients), it was 1.9% (RD: −0.01, 95% CI: −0.02-0.01, P = 0.23). We found no significant between-study heterogeneity (I 2 = 0%, P = 0.86). All three trials were judged to be at high risk of bias in two or more domains. Excluding the trial with recruitment starting before 2000 (Kentucky) 17 revealed no difference in the risk of minor stroke/TIA (RD: −0.01, 95% CI: −0.02-0.00, P = 0.21). The GRADE level of evidence for this outcome was judged to be moderate.
Thirty-day MI. Data on MI within 30 days of treatment were reported in three studies 13, 14, 16 . In the CEA group (1019 patients), MI occurred in 1.6% of patients, whereas in the CAS group (1751 patients), MI within 30 days of treatment occurred in 0.7% (RD: 0.01, 95% CI: −0.00-0.02, P = 0.13). The statistical heterogeneity was insignificant (I 2 = 0%, P = 0.67). All trials were judged to be at high risk of bias in two or more domains, and their recruitment period started after 2000. The GRADE level of evidence for this outcome was judged to be moderate.
Ipsilateral stroke during follow up. Data on long-term ipsilateral stroke were reported in two studies 13, 18 . The stroke rate was 4.3% in the CEA group (484 patients) and 3% in the CAS group (1206 patients) (OR: 1.05, 95% CI: 0.59-1.87, P = 0.86). The statistical heterogeneity was low (I 2 = 0%, P = 0.8). Both trials were judged to be at high risk of bias in two or more domains. None of the trials selected for analysis reported follow up longer than five years. Both trials started recruitment after 2000. The GRADE level of evidence for this outcome was judged to be moderate. Mortality during follow up. Data on long-term mortality were reported in two studies 13, 14 . In the CEA group (432 patients), long-term mortality was 9.5%, and in the CAS group (1157 patients), it was 12.3% (OR: 0.79, 95% CI: 0.55-1.15, P = 0.22). There was no significant between-study heterogeneity (I 2 = 0%, P = 0.74). Both trials were judged to be at high risk of bias in two or more domains. None of the trials selected for analysis reported follow up longer than five years. Both trials started recruitment after 2000. The GRADE level of evidence for this outcome was judged to be moderate. Ipsilateral minor stroke/TIA during follow up. Data on long-term ipsilateral minor stroke/TIA were reported in one trial 14 . In the CEA group (68 patients), no minor ipsilateral stroke/TIA occurred during follow up, and in the CAS group (68 patients), one patient developed a TIA during the follow-up period (1.5%) (OR: 0.33, 95% CI: 0.01-8.21, P = 0.5). The GRADE level of evidence for this outcome was judged to be low.
MI during follow up. No data on MI during follow up were reported in the selected trials. (Table 3 ). For this outcome parameter, the probability of BMT to be the best treatment was 99.9%.
Five trials provided data on long-term mortality 9, 10, [13] [14] [15] . With CEA as the reference, ORs and 95% CIs for long-term mortality were as follows: BMT, 1.43 (0.89-2.30) and CAS, 1.20 (0.65-2.21), with the result favouring CEA without reaching statistical significance (Table 3 ). For long-term mortality, the probabilities of CEA, CAS and BMT to be the best treatment were 66.6%, 27.6% and 5.8% respectively.
All but one trial 15 reported data on 30-day ipsilateral stroke. With BMT as reference treatment, ORs and 95% CIs for 30-day ipsilateral stroke were as follows: CAS, 2.37(1.07-5.26) and CEA, 1.52(0.48-4.77), with the result favouring BMT (Table 3) . For this outcome, the probability of BMT to be the best treatment was 100%.
Six trials provided data on long-term ipsilateral stroke 9, 10, 13, 15, 18, 19 . With CEA as the reference, ORs and 95% CIs for long-term ipsilateral stroke were as follows: BMT, 1.69 (1.41-2.02) and CAS, 0.97 (0.55-1.72), with statistically significant results in favour of CEA over BMT only (Table 3 ). For ipsilateral stroke during follow up, the probabilities of CEA, CAS and BMT to be the best treatment were 46.4%, 53.6% and 0%, respectively.
The results from network meta-analysis predictive interval showed that future trails are highly likely to change the direction of the treatment effect for patients with asymptomatic carotid disease, particularly so for BMT.
Discussion
We conducted a pairwise and network meta-analysis of treatment strategies for asymptomatic carotid disease including a total of 8954 patients from 11 randomised clinical trials. Pairwise treatment meta-analysis showed that CEA is superior to BMT in reducing the risk of long-term mortality and stroke. There were no statistical significant differences between CEA and CAS in terms of peri-interventional or long term ipsilateral stoke/mortality.
The value of CEA in reducing the risk of stroke in asymptomatic carotid artery stenosis is predominantly based on two seminal studies performed in the 1990s. The ACAS 9 was a well-conducted RCT that was halted at 2.7 years because of a projected 5.9% absolute risk reduction at five years favouring CEA. BMT in this trail were only in the form of Aspirin and a general discussion in cardiovascular risk reduction factors. The ACST trial 10 randomized 3120 asymptomatic carotid artery stenosis patients to immediate CEA or delayed surgery for symptoms only. Combining perioperative events and strokes, net risks were 6.9% vs. 10.9% at 5 years and 13.4% vs. 17.9% at 10 years.BMT improved significantly during these ten years with 82% of patient on lipid lowering by drugs by the end of trail compare to only 7% at the beginning of the trail.
In 2016, the results from two large RCTs comparing CEA with CAS in asymptomatic carotid stenosis patient were published. The CREST trial 21 and ACT 1 13 resolved the durability dilemma with CAS. However, these trials did not resolve the issue of generalisability of these findings into routine clinical practice, where rates of death and stroke may be much higher among patients undergoing carotid stenting 22 .
In CEA vs. BMT, the quality of the evidence was judged to be high according to the GRADE system. This was reduced to moderate/low for CEA vs. CAS as all trials included in the analysis were judged to be at high risk of bias in two or more domains.
Systematic review 23 of 47 studies (6 RCTs and 41 observational studies) investigating the evidence on management strategies for asymptomatic carotid stenosis also concluded that the evidence was not sufficiently robust or applicable to current clinical practice to allow clinicians to draw confident conclusions on the comparative effectiveness of management strategies for adults with asymptomatic carotid stenosis. Moresoli et al. 24 , published a meta-analysis of 11 studies (5 RCTs and 6 observational studies) on CAS vs CEA in asymptomatic carotid disease. The results of this meta-analysis corroborate our findings as there was no clinically significant differences between treatments for long-term stroke (RR, 1.24; 95% CI, 0.76-2.03) and the composite outcome of periprocedural stroke, death or MI, or long-term ipsilateral stroke (RR, 0.92; 95% CI, 0.70-1.21). Most recently, Kakkos SK et al. 25 published a meta-analysis of 9 RCTs comparing CEA with CAS in asymptomatic carotid disease patients. Regarding the long-term outcome of stroke or death rate at 30 days plus ipsilateral stroke during follow-up, this was significantly higher for CAS (3.64%) than for CEA (2.45%) (OR, 1.51; 95% CI, 1.02-2.24; P = 0.04; I2 = 0%). However, quality of evidence for all stroke outcomes was graded moderate.
The network meta-analysis is the first to be undertaken in this area. It demonstrates that CAS and CEA increase the risk of death and ipsilateral stroke at 30 days compared to BMT. This is an unsurprising finding given the well reported risks of revascularisation interventions. The network meta-analysis results favour CEA in the long term, but this finding is less conclusive.
CREST-2 26 and ACST-2 27 trials are currently running to provide level 1 evidence in regards of treatment strategy for asymptomatic carotid artery disease. CREST-2 consists of 2 parallel, RCTs. One trial will compare BMT to CEA BMT. The parallel trial will compare BMT to CAS plus BMT. An estimated 2480 participants will be enrolled in CREST-2 at approximately 120 sites in the United States and in several Canadian sites. ACST-2 is a large international RCT comparing CEA versus CAS in patients with asymptomatic carotid stenosis. ACST-2 is currently recruiting patients from over 112 centres in over 20 countries worldwide. The trial is on track to recruit 3600 patients by 2019. The results of our review should be interpreted with caution in view of the following limitations. The two major limitations to the pair-wise meta-analysis are variation in follow up period together with significant heterogeneity in BMT within and between the studies. Follow up period were between 30-days and 9 years. This variation will have an effect in reporting outcome measures using OR. This is particularly true when event rate is low, as in carotid trials. In terms of BMT, only one trail 15 adhered to current guidelines of aggressive medical therapy (blood pressure control, DM treatment, lipid lowering agents) together with lifestyle modification (exercise, smoking cessation and weight reduction). Antiplatelet were the only components of BMT in earlier trails with introduction to statin treatment in late 90s. No sufficient data are provided by the randomised clinical trials included in our review to allow us to perform meta-regression analysis to investigate the effect of statin and/ or aspirin on the outcomes. In addition, within CEA/CAS trial patients received different BMT regime (dual antiplatelet treatment if were allocated to CAS). However we tried to overcome these limitations by conducting sensitivity analysis excluding old studies and those with <5 years follow up.
There were also limitations in the NMA. The network geometry did not provide any closed loops across the competing interventions except for one trial that provided data on 30-day ipsilateral stroke only; therefore, we were not able to assess inconsistency between direct and indirect evidence. There was no direct comparison between CAS and BMT. There was a different time span between trials comparing CEA vs. BMT (1997 BMT ( -2015 and CEA vs. CAS (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) , which might challenge transitivity (assumption of similarity in the study characteristics between trails). Transitivity might be also challenged by the variation in the components of BMT and variation in the inclusion criteria. Similarly, the difference in follow up across trials and across the network may introduce heterogeneity and inconsistency, respectively.
Conclusions
Surgical intervention with CEA is superior to BMT in preventing long term ipsilateral stroke/mortality in asymptomatic carotid disease, but there is probably no difference between CEA and CAS. CREST-2 will clarify whether revascularization interventions provide long-term benefit to patients treated by current best-available medical therapy. We considered any type of stent including a closed or open cell design. BMT was implemented according to evidence-based guidelines; it mainly consisted of optimal antiplatelet therapy according to clinical practice at the participating centres, cholesterol-lowering agents (e.g. statin), antihypertensive medication and targeted risk factor modification.
Types of outcome measures. Primary outcomes
• Death and stroke occurring within 30 days of treatment or during the hospital stay for the index procedure (CEA or CAS) and during follow up.
Secondary outcomes
• Myocardial infarction (MI) occurring in the perioperative period (within 30 days or during the hospital stay) and during follow up. Data extraction and management. Two review authors (MB, IR) independently evaluated the studies and selected the studied that fulfilled the inclusion criteria for this review. A third author (GAA) then assess all the selected studie and ensure their eligibility for the inclusion criteria and also acted as an adjudicator in the event of disagreement. We developed a data extraction sheet, which was pilot-tested and refined accordingly. One review author (MB) extracted the data from the selected studies and a second review author (IR) crosschecked the collected data. Disagreements were resolved by discussion between the authors. The following data were collected:
• Study-related information (first author, year of publication, single-centre or multi-centre study).
• Baseline demographics and clinical characteristics of the study populations (age, gender, diabetes mellitus, hypertension, type of carotid intervention, type of antiplatelet therapy). • Outcome data, as outlined above.
Assessment of risk of bias in included studies. We applied the Cochrane tool for the assessment of the risk of bias of the selected trials 29 . Briefly, this tool evaluates six main domains: random sequence generation and allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias), and other sources of bias. For each individual domain, we classified studies into low, unclear, or high risk of bias. The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) working group system was utilised for grading the quality of evidence as high, moderate, low and very low, based on directness of evidence, within-study risk of bias, precision of effects estimates, heterogeneity, and risk of publication bias 30 .
Methods of analysis.
We used the RevMan 5.3 software (Cochrane collaboration, Copenhagen, Denmark) for pair-wise meta-analyses. Treatment effect estimates were calculated using the odds ratio (OR) or risk difference (RD) and 95% confidence interval (CI) to reflect the uncertainty of point estimate of effects. We based calculations using an intention-to-treat approach and all randomized participants were included in the analysis regardless of loss to follow up. The unit of analysis was the individual patient. For data synthesis, we used a fixed-effect model to calculate the pooled treatment effect and 95% CI for dichotomous outcome variables. We used a random-effects model when we found significant heterogeneity (defined as I 2 greater than 75%). We created a forest plot for each treatment effect.
We assessed inter-study heterogeneity visually using a forest plot. We also calculated the I 2 statistic to measure the amount of interstudy heterogeneity. We considered I 2 values less than 50% as indicative of low heterogeneity, I 2 values between 50% and 75% as indicative of moderate heterogeneity, and I 2 values greater than 75% as indicative of significant heterogeneity.
